HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings In Brief

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder: Net sales of $2.31 bil. for the second quarter of fiscal 2008 represent a 16% increase over the prior year, according to Feb. 1 release. Performance was fueled by "across-the-board gains in our geographic regions and product categories," President and CEO William P. Lauder says. Skin Care benefited from double-digit gains from La Mer as well as worldwide sales of Idealist Pore Minimizing Skin Refinisher by Estee Lauder and Acne Solutions Clear Skin System from Clinique, booking $831.2 mil. in net sales. Firm's makeup artist brands such as MAC and Bobbi Brown contributed 65% of incremental sales based on market expansion and solid product performances, company says; category did net sales of $827.3 mil. Fragrance sales of $520.5 mil. were driven by good results in Europe as well as recent launches Sean John Unforgivable Woman, Estee Lauder Pleasures Delight, Dreaming by Tommy Hilfiger and Tom Ford for Men. Hair care sales were $110.4 mil., with notable contributions from Aveda and Bumble and bumble. Asia Pacific was firm's top-performing region, with sales growth of 21.7% on a reported basis and sales of $347.4 mil. The U.S. retail slowdown in department stores was offset by other channels, including freestanding stores, hair salons and Internet sales, CEO Lauder noted during earnings call...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel